白云山：产品“冻干人用狂犬病疫苗”取得注册证

Group 1 - The core point of the article is that Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has received approval from the National Medical Products Administration for its freeze-dried human rabies vaccine, which is a significant development for the company [1] - As of the end of the report, Baiyunshan's market capitalization is 42 billion yuan [1] - The revenue composition for Baiyunshan in the first half of 2025 is as follows: 69.32% from large commercial, 16.79% from health, 12.53% from traditional Chinese medicine, 1.07% from other businesses, and 0.3% from miscellaneous [1]